Classification analysis of P-glycoprotein substrate specificity

Journal of Drug Targeting

Volumn 11, Issue 7, 2003, Pages 391-406

  Didziapetris, Remigijus ^a   Japertas, Pranas ^a,b   Avdeef, Alex ^c   Petrauskas, Alanas ^a  

^a Pharma Algorithms Inc   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

^c PION INC   (United States)

Author keywords

ADME predictions; Blood brain barrier; CNS; Fuzzy specificity; P glycoprotein; Property based design

Indexed keywords

ABAMECTIN; ADENOSINE TRIPHOSPHATASE; APAFANT; AVERMECTIN; BERBERINE; CELIPROLOL; CETIRIZINE; COLCHICINE; CYCLOSPORIN A; DAUNORUBICIN; DIGOXIN; DIPYRIDAMOLE; DOCETAXEL; DOMPERIDONE; EBASTINE; FAMOTIDINE; FEXOFENADINE; GLYCOPROTEIN P; IMATINIB; IVERMECTIN; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL; QUINIDINE; RESERPINE; SAQUINAVIR; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACTIVE TRANSPORT; ANIMAL CELL; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IONIZATION; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PROTEIN FUNCTION; REVIEW; SOLVATION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATASES; ALGORITHMS; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; CHEMISTRY, PHYSICAL; DOGS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FUZZY LOGIC; GENES, MDR; HUMANS; HYDROGEN; LLC-PK1 CELLS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MOLECULAR WEIGHT; P-GLYCOPROTEIN; SUBSTRATE SPECIFICITY; SWINE; TRANSFECTION; TRANSGENES;

EID: 1842535990     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860310001648248     Document Type: Review

References (166)

1. Abel, S., Beaumont, K.C., Crespi, C.L., Eve, M.D., Fox, L., Hyland, R., Jones, B.C., Muirhead, G.J., Smith, D.A., Venn, R.F. and Walker, D.K. (2001) "POtential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man", Xenobiotica 31, 665-676.
2. Abraham, M.H. (1993) "SCales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes", Chem. Soc. Rev. 22, 73-83.
3. Abraham, M.H. and Roses, M. (1994) "HYdrogen Bonding. 38. Effects of solute structure and mobile phase composition on reversed-phase high-performance liquid chromatographic capacity factors", J. Phys. Org. Chem. 7, 672-684.
4. Abraham, M.H., Poole, C.F. and Poole, S.K. (1996) "SOlute effects on reversed-phase thin-layer chromatography. A linear free energy relationship analysis", J. Chromatogr. 749, 201-209.
5. Abraham, M.H., Chadha, H.S., Martins, F., Mitchell, R.C., Bradbury, M.W. and Aratton, J.A. (1999) "HYdrogen bonding part 46: a review of the correlation and prediction of transport properties by an LFER method: Physicochemical properties, brain penetration and skin permeability", Pestic. Sci. 55, 78-88.
6. Adachi, Y, Suzuki, H. and Sugiyama, Y. (2001) "COmparative studies on in vitro methods for evaluating in vivo function of MDR1 P-Glycoprotein", Pharm. Res. 18, 1660-1668.
7. Aksentijevich, I., Cardarelli, C.O., Pastan, I. and Gottesman, M.M. (1996) "REtroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity", Clin. Cancer Res. 2, 973-980.
8. Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I. and Gottesman, M.M. (1999) "BIochemical, cellular, and pharmacological aspects of the multidrug transporter", Annu Rev. Pharmacol. Toxicol 39, 361-398.
9. Ayesh, S., Shao, Y.M. and Stein, W.D. (1996) "CO-operative, competitive and non-competitive interactions between modulators of P-glycoprotein", Biochim. Biophys. Acta 1316, 8-18.
10. Ayrton, A. and Morgan, P. (2001) "ROle of transport proteins in drug absorption, distribution and excretion", Xenobiotica 31, 469-497.
11. Bacher, G., Nickel, B., Emig, P., Vanhoefer, U., Seeber, S., Shandra, A., Klenner, T. and Beckers, T. (2001) "D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity", Cancer Res. 61, 392-399.
12. Bain, L.J. and LeBlanc, G.A. (1996) "INteraction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein", Toxicol. Appl. Pharmacol. 141, 288-298.
13. Bakken, G.A. and Jurs, P.C. (2000) "CLassification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis", J. Med. Chem. 43, 4534-4541.
14. Barecki-Roach, M., Wang, E.J. and Johnson, W.W. (2003) "MAny P-glycoprotein substrates do not inhibit the transport process across cell membranes", Xenobiotica 33, 131-140.
15. Barnes, K.M., Dickstein, B., Cutler, G.B. Jr., Fojo, T. and Bates, S.E. (1996) "STeroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells", Biochemistry 35, 4820-4827.
16. Begley, D.J., Lechardeur, D., Chen, Z.D., Rollinson, C., Bardoul, M. and Roux, F., Scherman, D., Abbott, N.J. (1996) "FUnctional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4", J. Neurochem. 67, 988-995.
17. Borgnia, M.J., Eytan, G.D. and Assaraf, Y.G. (1996) "COmpetition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity", J. Biol. Chem. 271, 3163-3171.
18. Callaghan, R. and Higgins, C.F. (1995) "INteraction of tamoxifen with the multidrug resistance P-glycoprotein", Br. J. Cancer 71, 294-299.
19. Chen, W., Yang, J.Z., Andersen, R., Nielsen, L.H. and Borchardt, R.T. (2002) "EValuation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model" J. Pharmacol. Exp. Ther. 303, 849-857.
20. Chen, C., Hanson, E., Watson, J.W. and Lee, J.S. (2003) "P-Glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists", Drug Metab. Dispos. 31, 312-318.
21. Chiba, P., Ecker, G., Schmid, D., Drach, J., Tell, B., Goldenberg, S. and Gekeler, V. (1996) "STructural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance", Mol. Pharmacol. 49, 1122-1130.
22. Chishty, M., Reichel, A., Siva, J., Abbott, N.J. and Begley, D.J. (2001) "AFfinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines", J. Drug Target. 9, 223-228.
23. Cisternino, S., Rousselle, C., Dagenais, C. and Scherrmann, J.M. (2001) "SCreening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice", Pharm. Res. 18, 183-190.
24. Cummins, C.L., Jacobsen, W. and Benet, L.Z. (2002) "UNmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4", J. Pharmacol. Exp. Ther. 300, 1036-1045.
25. Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R. and Kim, R.B. (1999) "OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine", Drug Metab. Dispos. 27, 866-871.
26. Dagenais, C., Ducharme, J. and Pollack, G.M. (2001a) "UPtake and efflux of the peptidic delta-opioid receptor agonist", Neurosci. Lett. 301, 155-158.
27. Dagenais, C., Zong, J., and Pollack, G.M. (2001b) "EFfect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds", Pharm. Res. 18, 957-963.
28. Dai, H., Marbach, P., Lemaire, M., Hayes, M. and Elmquist, W.F. (2003) "DIstribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux", J. Pharmacol. Exp. Ther. 304(3), 1085-1092.
29. Dantzig, A.H., Shepard, R.L., Law, K.L., Tabas, L., Pratt, S., Gillespie, J.S., Binkley, S.N., Kuhfeld, M.T., Starling, J.J. and Wrighton, S.A. (1999) "SElectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities", J. Pharmacol. Exp. Ther. 290, 854-862.
30. van Der Kaaden, J.E., Hemscheidt, T.K. and Mooberry, S.L. (2001) "MAppain, a new cytotoxic prenylated stilbene from Macaranga mappa", J. Nat. Prod. 64, 103-105.
31. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M.M. and Ambudkar, S.V. (1997) "EVidence for two nonidentical drug-interaction sites in the human P-glycoprotein", Proc. Natl Acad. Sci. USA 94, 10594-10599.
32. Doan, K.M., Humphreys, J.E., Webster, L.O., Wring, S.A., Shampine, L.J., Serabjit-Singh, C.J., Adkison, K.K. and Polli, J.W. (2002) "PAssive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs", J. Pharmacol. Exp. Ther. 303, 1029-1037.
33. Doppenschmitt, S., Spahn-Langguth, H., Regardh, C.G. and Langguth, P. (1999) "ROle of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein", J. Pharm. Sci. 88, 1067-1072.
34. Ecker, G., Chiba, P., Hitzler, M., Schmid, D., Visser, K., Cordes, H.P., Csollei, J., Seydel, J.K. and Schaper, K.J. (1996) "STructure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance", J. Med. Chem. 39, 4767-4774.
35. Ecker, G., Huber, M., Schmid, D. and Chiba, P. (1999) "THe importance of a nitrogen atom in modulators of multidrug resistance", Mol. Pharmacol. 56, 791-796.
36. Ekins, S., Kim, R.B., Leake, B.F., Dantzig, A.H., Schuetz, E.G., Lan, L.B., Yasuda, K., Shepard, R.L., Winter, M.A., Schuetz, J.D., Wikel, J.H. and Wrighton, S.A. (2002a) "APplication of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates", Mol. Pharmacol. 61, 974-981.
37. Ekins, S., Kim, R.B., Leake, B.F., Dantzig, A.H., Schuetz, E.G., Lan, L.B., Yasuda, K., Shepard, R.L., Winter, M.A., Schuetz, J.D., Wikel, J.H. and Wrighton, S.A. (2002b) "THree-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein", Mol. Pharmacol. 61, 964-973.
38. Eneroth, A., Astrom, E., Hoogstraate, J., Schrenk, D., Conrad, S., Kauffmann, H.M. and Gjellan, K. (200 1) "EValuation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction", Eur. J. Pharm. Sci. 12, 205-214.
39. Ertl, P., Rohde, B. and Selzer, P. (2000) "FAst calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties", J. Med. Chem. 43, 3714-3717.
40. Essodaigui, M., Broxterman, H.J. and Garnier-Suillerot, A. (1998) "KInetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein", Biochemistry 37, 2243-2250.
41. Etievant, C., Barret, J.M., Kruczynski, A., Perrin, D. and Hill, B.T. (1998) "VInflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp -mediated multidrug resistance in vivo and in vitro", Invest. New Drugs 16, 3-17.
42. Eytan, G.D., Regev, R., Oren, G. and Assaraf, Y.G. (1996) "THe role of passive transbilayer drug movement in multidrug resistance and its modulation", J. Biol. Chem. 271, 12897-12902.
43. Faber, K.N., Muller, M. and Jansen, P.L. (2003) "DRug transport proteins in the liver", Adv. Drug Deliv. Rev. 55(1), 107-124.
44. Ferte, J. (2000) "ANalysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane", Eur. J. Biochem. 267, 277-294.
45. Garrigues, A., Loiseau, N., Delaforge, M., Ferte, J., Garrigos, M., Andre, F. and Orlowski, S. (2002) "CHaracterization of two pharmacophores on the multidrug transporter P-glycoprotein", Mol. Pharmacol. 62, 1288-1298.
46. Glynn, S.L. and Yazdanian, M. (1998) "IN vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents", J. Pharm. Sci. 87, 306-310.
47. Gottesman, M.M., Fojo, T. and Bates, S.E. (2002) "MUltidrug resistance in cancer: Role of ATP-dependent transporters", Nat. Rev. Cancer 2, 48-58.
48. Gourdeau, H., Genne, P., Kadhim, S., Bibeau, L., Duchamp, O., Ouellet, F., DeMuys, J.M., Bouffard, D.Y. and Attardo, G. (2002) "ANtitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts", Cancer Chemother. Pharmacol. 50, 490-496.
49. Gros, P., Talbot, F., Tang-Wai, D., Bibi, E. and Kaback, H.R. (1992) "LIpoAhilic cations: a group of model substrates for the multidrug-resistance transporter", Biochemistry 31, 1992-1998.
50. Hamilton, K.O., Backstrom, G., Yazdanian, M.A. and Audus, K.L. (2001) "P-glycoprotein efflux pump expression and activity in Calu-3 cells", J. Pharm. Sci. 90, 647-658.
51. Hansch, C., Kurup, A., Garg, R. and Gao, H. (2001) "CHem-Informatics aAd QSAR: a review of QSAR lacking positive hydrophobic terms", Chem. Rev. 101, 619-672.
52. Hiessbock, R., Wolf, C., Richter, E., Hitzler, M., Chiba, P., Kratzel, M. and Ecker, G. (1999) "SYnthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines", J. Med. Chem. 42, 1921-1926.
53. Horio, M., Chin, K.V., Currier, S.J., Goldenberg, S., Williams, C., Pastan, I., Gottesman, M.M. and Handler, J. (1989) "TRansepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia", J. Biol. Chem. 264, 14880-14884.
54. Hunter, J., Hirst, B.H. and Simmons, N.L. (1993) "DRug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers", Pharm. Res. 10, 74-749.
55. Ishikawa, T., Muller, M., Klunemann, C., Schaub, T. and Keppler, D. (1990) "ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates", J. Biol. Chem. 265, 19279-19286.
56. Ito, T., Yano, I., Tanaka, K. and Inui, K.I. (1997) "TRansport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1", J. Pharmacol. Exp. Ther. 282, 955-960.
57. Japertas, P., Didziapetris, R. and Petrauskas, A. (2002) "FRagmental methods in the design of new compounds. Applications of advanced algorithm builder", Quant. Struct.-Act. Relat. 21, 23-37.
58. Japertas, P., Didziapetris, R. and Petrauskas, A. (2003) "FRagmental methods in the analysis of biological activities of diverse compound sets", Curr. Mini-Rev. Med. Chem. 3, 797-803.
59. Jonker, J.W., Wagenaar, E., van Deemter, L., Gottschlich, R., Bender, H.M., Dasenbrock, J. and Schinkel, A.H. (1999) "ROle of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug", Br. J. Pharmacol. 127, 43-50.
60. Karlsson, J., Kuo, S.M., Ziemniak, J. and Artursson, P. (1993) "TRansport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein", Br. J. Pharmacol. 110, 1009-1016.
61. Kavallaris, M., Madafiglio, J., Norris, M.D. and Haber, M. (1993) "REsistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells", Biochem. Biophys. Res. Commun. 190, 79-85.
62. Kerns, E.H. and Di, L. (2003) "PHarmaceutical profiling in drug discovery", Drug Discov. Today 8, 316-323.
63. Kessel, D., Beck, W.T., Kukuruga, D. and Schulz, V. (1991) "CHaracterization of multidrug resistance by fluorescent dyes" , Cancer Res. 51, 4665-4670.
64. Kim, R.B. (2002) "DRugs as P-glycoprotein substrates, inhibitors, and inducers", Drug Metab. Rev. 34, 47-54.
65. Kim, R.B., Fromm, M.F., Wandel, C., Leake, B., Wood, A.J., Roden, D.M. and Wilkinson, G.R. (1998) "THe drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors", J. Clin. Investig 101, 289-294.
66. Kim, R.B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M.F., Dempsey, P.J., Roden, M.M., Belas, F., Chaudhary, A.K., Roden, D.M., Wood, A.J. and Wilkinson, G.R. (1999) "INterrelationship between substrates and inhibitors of human CYP3A, P-glycoprotein", Pharm. Res. 16, 408-414.
67. Klopman, G., Shi, L.M. and Ramu, A. (1997) "QUantitative structure-activity relationship of multidrug resistance reversal agent", Mol. Pharmacol. 52, 323-334.
68. Kubinyi, H. (1997) "QSAR and 3D QSAR in drug design. Part 2: applications and problems", Drug Discovery Today 2, 538-546.
69. Kubinyi, H. (1998) "COmparative molecular field analysis (CoMFA)", In: Schleyer, P.V.R., Allinger, N.L., Clark, T., Gasteiger, J., Kollman, P.A., Schaefer, III, H.F. and Schreiner, P.R., eds, The Encyclopedia of Computational Chemistry 4, pp 449-460.
70. Kumar, S., Kwei, G.Y., Poon, G.K., Iliff, S.A., Wang, Y., Chen, Q., Franklin, R.B., Didolkar, V., Wang, R.W., Yamazaki, M., Chiu, S.H., Lin, J.H., Pearson, P.G. and Baillie, T.A. (2003) "PHarmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: Role of CYP3A and P-glycoprotein", J. Pharmacol. Exp. Ther. 304, 1161-1171.
71. Lang, V.B., Langguth, P., Ottiger, C., Wunderli-Allenspach, H., Rognan, D., Rothen-Rutishauser, B., Perriard, J.C., Lang, S., Biber, J. and Merkle, H.P. (1997) "STructure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers", J. Pharm. Sci. 86, 846-853.
72. de Lange, E.C., Marchand, S., van den Berg, D., van der Sandt, I.C., de Boer, A.G., Delon, A., Bouquet, S. and Couet, W. (2000) "IN vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin", Eur. J. Pharm. Sci. 12, 85-93.
73. Lankas, G.R., Cartwright, M.E. and Umbenhauer, D. (1997) "P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity", Toxicol. Appl. Pharmacol. 143, 357-365.
74. Lee, J.S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A.T. and Bates, S.E. (1994) "RHodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen", Mol. Pharmacol. 46, 627-638.
75. Lee, K., Ng, C., Brouwer, K.L. and Thakker, D.R. (2002) "SEcretory transport of ranitidine and famotidine across Caco-2 cell monolayers", J. Pharmacol. Exp. Ther. 303, 574-580.
76. Leusch, A., Volz, A., Muller, G., Wagner, A., Sauer, A., Greischel, A. and Roth, W. (2002) "ALtered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice", Eur. J. Pharm. Sci. 16, 119-128.
77. Liang, E., Proudfoot, J. and Yazdanian, M. (2000) "MEchanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers", Pharm. Res. 17, 1168-1174.
78. Lin, J.H. (2003) "DRug-drug interaction mediated by inhibition and induction of P-glycoprotein", Adv. Drug Deliv. Rev. 55, 53-81.
79. Lin, J.H. and Yamazaki, M. (2003) "ROle of P-glycoprotein in pharmacokinetics: Clinical implications", Clin. Pharmacokinet. 42, 59-98.
80. Litman, T., Zeuthen, T., Skovsgaard, T. and Stein, W.D. (1997) "STructure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity", Biochim. Biophys. Acta 1361, 159-168.
81. Maeng, H.J., Yoo, H.J., Kim, I.W., Song, I.S., Chung, S.J. and Shim, C.K. (2002) "P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers", J. Pharm. Sci. 91, 2614-2621.
82. Martin, C., Berridge, G., Higgins, C.F., Mistry, P., Charlton, P. and Callaghan, R. (2000a) "COmmunication between multiple drug binding sites on P-glycoprotein", Mol. Pharmacol 58, 624-632.
83. Martin, C., Berridge, G., Mistry, P., Higgins, C.F., Charlton, P. and Callaghan, R. (2000b) "DRug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis", Biochemistry 39, 11901-11906.
84. Martin, C., Higgins, C.F. and Callaghan, R. (2001) "THe vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein", Biochemistry 40, 15733-15742.
85. Matsuzaki, J., Yamamoto, C., Miyama, T., Takanaga, H., Matsuo, H., Ishizuka, H., Kawahara, Y., Kuwano, M., Naito, M., Tsuruo, T. and Sawada, Y. (1999) "COntribution of P-glycoprotein to unitrolol efflux across blood-brain barrier", Biopharm. Drug Dispos. 20, 85-90.
86. von Moltke, L.L. and Greenblatt, D.J. (2000) "DRug transporters in psychopharmacology - are they important?", J. Clin. Psychopharmacol. 20, 291-294.
87. Norinder, U. and Haeberlein, M. (2002) "COmputational approaches to the prediction of the blood-brain distribution", Adv. Drug Deliv. Rev. 54, 291-313.
88. Osterberg, T. and Norinder, U. (2000) "PRediction of polar surface area and drug transport processes using simple parameters and PLS statistics", J. Chem. Inf. Comput. Sci. 40, 1408-1411.
89. Pajeva, I.K. and Wiese, M. (2002) "PHarmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (hypothesis)", J. Med. Chem. 45, 5671-5686.
90. Pascaud, C., Garrigos, M. and Orlowski, S. (1998) "MUltidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents", Biochem. J. 333, 351-358.
91. Pauli-Magnus, C., von Richter, O., Burk, O., Ziegler, A., Mettang, T., Eichelbaum, M. and Fromm, M.F. (2000) "CHaracterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein", J. Pharmacol. Exp. Ther. 293, 376-382.
92. Pauli-Magnus, C., Murdter, T., Godel, A., Mettang, T., Eichelbaum, M., Klotz, U. and Fromm, M.F. (2001a) "P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin", Naunyn Schmiedebergs Arch. Pharmacol. 363, 337-343.
93. Pauli-Magnus, C., Rekersbrink, S., Klotz, U. and Fromm, M.F. (2001b) "INteraction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein", Naunyn Schmiedebergs Arch. Pharmacol. 364, 551-557.
94. Penzotti, J.E., Lamb, M.L., Evensen, E. and Grootenhuis, P.D. (2002) "A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein", J. Med. Chem. 45, 1737-1740.
95. Platts, J.A., Butina, D., Abraham, M.H. and Hersey, A. (1999) "EStimation of molecular linear free energy relationship descriptors using a group contribution approach", J. Chem. Inf. Comput. Sci. 39, 835-845.
96. Polli, J.W., Wring, S.A., Humphreys, J.E., Huang, L., Morgan, J.B., Webster, L.O. and Serabjit-Singh, C.S. (2001) "RAtional use of in vitro P-glycoprotein assays in drug discovery", J. Pharmacol. Exp. Ther. 299, 620-628.
97. Prueksaritanont, T., Meng, Y, Ma, B., Leppert, P., Hochman, J., Tang, C., Perkins, J., Zrada, M., Meissner, R., Duggan, M.E. and Lin, J.H. (2002) "DIfferences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein", Xenobiotica 32, 207-220.
98. Rosenberg, M.F., Callaghan, R., Ford, R.C. and Higgins, C.F. (1997) "STructure of the multidrug resistance P-glycoprotein to 2.5 nm. resolution determined by electron microscopy and image analysis", J. Biol. Chem. 272, 10685-10694.
99. Rosenberg, M.F., Kamis, A.B., Callaghan, R., Higgins, C.F. and Ford, R.C. (2003) "THree-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding", J. Biol. Chem. 278, 8294-8299.
100. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993a) "P-glycoprotein-mediated transcellular transport of MDR-reversing agents", FEBS Lett. 324, 99-102.
101. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993b) "HUman P-glycoprotein transports cyclosporin A and FK506", J. Biol. Chem. 268, 6077-6080.
102. Saitoh, H. and Aungst, B.J. (1995) "POssible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine", Pharm. Res. 12, 1304-1310.
103. Saitoh, H., Gerard, C. and Aungst, B.J. (1996) "THe secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: A mechanism contributing to poor oral absorption", J. Pharmacol. Exp. Ther. 278, 205-211.
104. Saitoh, H., Hatakeyama, M., Eguchi, O., Oda, M. and Takada, M. (1998) "INvolvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine", J. Pharm. Sci. 87, 73-75.
105. van der Sandt, I.C., Smolders, R., Nabulsi, L., Zuideveld, K.P., de Boer, A.G. and Breimer, D.D. (2001) "ACtive efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier", Eur. J. Pharm. Sci. 14, 81-86.
106. Sarkadi, B., Price, E.M., Boucher, R.C., Germann, U.A. and Scarborough, G.A. (1992) "EXpression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase", J. Biol. Chem. 267, 4854-4858.
107. Sawamoto, T., Van Gelder, T., Christians, U., Okamura, N., Jacobsen, W. and Benet, L. (2001) "MEmbrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1-MDCK cell monolayers", J. Heart Lung Transplant. 20, 234-235.
108. Scala, S., Akhmed, N., Rao, U.S., Paull, K., Lan, L.B., Dickstein, B., Lee, J.S., Elgemeie, G.H., Stein, W.D. and Bates, S.E. (1997) "P-glycoprotein substrates and antagonists cluster into two distinct groups", Mol. Pharmacol. 51, 1024-1033.
109. Schinkel, A.H. (1999) "P-glycoprotein, a gatekeeper in the blood-brain barrier", Adv. Drug Deliv. Rev. 36, 179-194.
110. Schinkel, A.H. and Jonker, J.W. (2003) "MAmmalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview", Adv. Drug Deliv. Rev. 55, 3-29.
111. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., Berns, A.J.M. and Borst, P. (1994) "DIsruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs", Cell 77, 491-502.
112. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A. and Borst, P. (1995) "ABsence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A", J. Clin. Investig. 96, 1698-1705.
113. Schinkel, A.H., Wagenaar, E., Mol, C.A. and van Deemter, L. (1996) "P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs", J. Clin. Investig. 97, 2517-2524.
114. Schmid, D., Ecker, G., Kopp, S., Hitzler, M. and Chiba, P. (1999) "STructure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements", Biochem. Pharmacol. 58, 1447-1456.
115. Schwab, D., Fischer, H., Tabatabaei, A., Poli, S. and Huwyler, J. (2003) "COmparison of in vitro p-glycoprotein screening assays: Recommendations for their use in drug discovery", J. Med. Chem. 46, 1716-1725.
116. Seelig, A. (1998) "A general pattern for substrate recognition by P-glycoprotein", Eur. J. Biochem. 251, 252-261.
117. Seelig, A. and Landwojtowicz, E. (2000) "STructure-activity relationship of P-glycoprotein substrates and modifiers", Eur. J. Pharm. Sci. 12, 31-40.
118. Seelig, A., Landwojtowicz, E., Fisher, H. and Li Blatter, X. (2003) "TOwards P-glycoprotein structure-activity relationships", In: Van der Waterbeemd, Lennernas and Arthurson, eds, Drug BioAvailability/Estimation of Solubility, Permeability and Absorption, pp 461-492.
119. Selassie, C.D., Hansch, C. and Khwaja, T.A. (1990) "STructure-activity relationships of antineoplastic agents in multidrug resistance", J. Med. Chem. 33, 1914-1919.
120. Shapiro, A.B. and Ling, V. (1997) "POsitively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities", Eur. J. Biochem. 250, 130-137.
121. Sharma, R.P., Bhandari, N., Tsunoda, M., Riley, R.T., Voss, K.A. and Meredith, F.I. (2000) "FUmonisin toxicity in a transgenic mouse model lacking the mdr1a/1b P-glycoprotein genes", Environ. Toxicol. Pharmacol. 8, 173-182.
122. Sharom, F.J. (1997) "THeHP-glycoprotein efflux pump: how does it transport drugs?", J. Membr. Biol. 160, 161-175.
123. Sharom, F.J., Yu, X., DiDiodato, G. and Chu, J.W. (1996) "SYnthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport", Biochem. J. 320, 421-428.
124. Sills, G.J., Kwan, P., Butler, E., de Lange, E.C., van den Berg, D.J. and Brodie, M.J. (2002) "P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice", Epilepsy Behav. 3, 427-432.
125. Spahn-Langguth, H., Baktir, G., Radschuweit, A., Okyar, A., Terhaag, B., Ader, P., Hanafy, A. and Langguth, P. (1998) "P-glycoprotein transporters and the gastrointestinaE tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound", Int. J. Clin. Pharmacol. Ther. 36, 16-24.
126. Stormer, E., von Moltke, L.L., Perloff, M.D. and Greenblatt, D.J. (2001) "P-glycoprotein interactions of nefazodone and trazodone in cell culture", J. Clin. Pharmacol. 41, 708-714.
127. Stormer, E., von Moltke, L.L., Perloff, M.D. and Greenblatt, D.J. (2002) "DIfferential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture", Pharm. Res. 19, 1038-1045.
128. Stouch, T.R. and Gudmundsson, O. (2002) "PRogress in understanding the structure-activity relationships of P-glycoprotein", Adv. Drug Deliv. Rev. 54, 315-328.
129. Susanto, M. and Benet, L.Z. (2002) "CAn the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?", Pharm. Res. 19, 457-462.
130. Takara, K., Tanigawara, Y, Komada, F., Nishiguchi, K., Sakaeda, T. and Okumura, K. (2000) "THe novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein", Jpn J. Cancer Res. 91, 248-254.
131. Takara, K., Sakaeda, T., Yagami, T., Kobayashi, H., Ohmoto, N., Horinouchi, M., Nishiguchi, K. and Okumura, K. (2002) "CYtotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines", Biol. Pharm. Bull. 25, 771-778.
132. Tamai, I., Kido, Y, Yamashita, J., Sai, Y. and Tsuji, A. (2002) "BLood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine", J. Drug Target. 8, 383-393.
133. Tang, F. and Borchardt, R.T. (2002) "CHaracterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE", Pharm. Res. 19, 787-793.
134. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T. and Hori, R. (1992) "TRansport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)", J. Pharmacol. Exp. Ther. 263, 840-845.
135. Terao, T., Hisanaga, E., Sai, Y., Tamai, I. and Tsuji, A. (1996) "ACtive secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier", J. Pharm. Pharmacol. 48, 1083-1089.
136. Testa, B., Crivori, P., Reist, M. and Carrupt, P.A. (2000) "THe Influence of lipophilicity on the pharmacokinetic behaviour of drugs: Concepts and examples", Persp. Drug Disc. Design 19, 179-211.
137. Thompson, S.J., Koszdin, K. and Bernards, C.M. (2000) "OPiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein", Anesthesiology 92, 1392-1399.
138. Tkaczyk-Gobis, K., Tarasiuk, J., Seksek, O., Stefanska, B., Borowski, E. and Garnier-Suillerot, A. (2001) "TRansport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells", Eur. J. Pharmacol. 413(2-3), 131-141.
139. Tmej, C., Chiba, P., Huber, M., Richter, E., Hitzler, M., Schaper, K.J. and Ecker, G. (1998) "A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance", Arch. Pharm. (Weinheim) 331, 233-240.
140. Tmej, C., Chiba, P., Schaper, K.J., Ecker, G. and Fleischhacker, W. (1999) "ARtificial neural networks as versatile tools for prediction of MDR-modulatory activity", Adv. Exp. Med. Biol. 457, 95-105.
141. Toffoli, G., Simone, F., Corona, G., Raschack, M., Cappelletto, B., Gigante, M. and Boiocchi, M. (1995) "STructure-activity relationship of verapamil analogs and reversal of multidrug resistance", Biochem. Pharmacol. 50, 1245-1255.
142. Tohda, H., Yasui, A., Yasumoto, T., Nakayasu, M., Shima, H.,
143. Tolle-Sander, S., Rautio, J., Wring, S., Polli, J.W. and Polli, J.E. (2003) "MIdazolam exhibits characteristics of a highly permeable P-glycoprotein substrate", Pharm. Res. 20, 757-764.
144. Uhr, M., Steckler, T., Yassouridis, A. and Holsboer, F (2000) "PEnetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption", Neuropsychopharmacology 22, 380-387.
145. Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W. and Kopple, K.D. (2002) "MOlecular properties that influence the oral bioavailability of drug candidates", J. Med. Chem. 45, 2615-2623.
146. Wacher, V.J., Salphati, L. and Benet, L.Z. (2001) "ACtive secretion and enterocytic drug metabolism barriers to drug absorption", Adv. Drug Deliv. Rev. 46, 89-102.
147. Wagner, D., Spahn-Langguth, H., Hanafy, A., Koggel, A. and Langguth, P. (200F) "INtestinal drug efflux: formulation and food effects", Adv. Drug Deliv. Rev. 50, S13-S31.
148. Wandel, C., Kim, R., Wood, M. and Wood, A. (2002) "INteraction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein", Anesthesiology 96, 913-920.
149. van De Waterbeemd, H., Smith, D.A., Beaumont, K. and Walker, D.K. (2001) "PROperty-based design: optimization of drug absorption and pharmacokinetics", J. Med. Chem. 44, 1313-1333.
150. van de Waterbeemd, H. and Gifford, E. (2003) "ADMET in silico modelling: Towards prediction paradise?", Nat. Rev. Drug Discov. 2, 192-204.
151. Wielinga, P.R., Westerhoff, H.V. and Lankelma, J. (2000) "THe relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells", Eur. J. Biochem. 267, 649-657.
152. Wils, P., Phung-Ba, V., Warnery, A., Lechardeur, D., Raeissi, S., Hidalgo, I.J. and Scherman, D. (1994) "POlarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers", Biochem. Pharmacol. 48, 1528-1530.
153. Yamamoto, C., Murakami, H., Koyabu, N., Takanaga, H., Matsuo, H., Uchiumi, T., Kuwano, M., Naito, M., Tsuruo, T., Ohtani, H. and Sawada, Y. (2002) "COntribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier", J. Pharm. Pharmacol. 54, 1055-1063.
154. Yamazaki, M., Neway, W.E., Ohe, T., Chen, I., Rowe, J.F., Hochman, J.H., Chiba, M. and Lin, J.H. (2001) "IN vitro substrate identification studies for p-glycoprotein-mediated transport: Species difference and predictability of in vivo results", J. Pharmacol. Exp. Ther. 296, 723-735.
155. Yasuda, K., Lan, L.B., Sanglard, D., Furuya, K., Schuetz, J.D. and Schuetz, E.G. (2002) "INteraction of cytochrome P450 3A inhibitors with P-glycoprotein", J. Pharmcol. Exp. Ther. 303, 323-332.
156. Young, A.M., Allen, C.E. and Audus, K.L. (2003) "EFflux transporters of the human placenta", Adv. Drug Deliv. Rev. 55, 125-132.
157. Yu, D.K. (1999) "THe contribution of P-glycoprotein to pharmacokinetic drug-drug interactions", J. Clin. Pharmacol. 39, 1203-1211.
158. Yu, E.W., McDermott, G., Zgurskaya, H.I., Nikaido, H. and Koshland, D.E. Jr. (2003) "STructural Basis of multiple drug-binding capacity of the AcrB multidrug efflux pump", Science 300, 976-980.
159. Yusa, K. and Tsuruo, T. (1989) "REversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells", Cancer Res. 49, 5002-5006.
160. Zamora, J.M., Pearce, H.L. and Beck, W.T. (1988) "PHysical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells", Mol. Pharmacol. 33, 454-462.
161. Zhang, Y. and Benet, L.Z. (1998) "CHaracterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers", Pharm. Res. 15, 1520-1524.
162. Zhang, Y., Guo, X., Lin, E.T. and Benet, L.Z. (1998) "OVerlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor", Drug Metab. Dispos. 26, 360-366.
163. Zhang, Y., Bachmeier, C. and Miller, D.W. (2003) "IN vitro and in vivo models for assessing drug efflux transporter activity", Adv. Drug Deliv. Rev. 55, 31-51.
164. Zhao, Y.H., Le, J., Abraham, M.H., Hersey, A., Eddershaw, P.J., Luscombe, C.N., Butina, D., Beck, G., Sherborne, B., Cooper, I., Platts, J.A. and Butina, D. (2001) "EValuation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors", J. Pharm. Sci. 90, 749-784.
165. Zmuidinavicius, D., Didziapetris, R., Japertas, P., Avdeef, A. and Petrauskas, A. (2003a) "CLassification structure-activity relations (C-SAR) in prediction of human intestinal absorption", J. Pharm. Sci. 92, 621-633.
166. Zmuidinavicius, D., Japertas, P., Petrauskas, A. and Didziapetris, R. (200Tb) "PRogress in toxinformatics: the challenge of predicting acute toxicity", Curr. Top. Med. Chem. 3, 1301-1314.